|
1
|
Powles T, Staehler M, Ljungberg B,
Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M,
Kuczyk MA, et al: Updated EAU guidelines for clear cell renal
cancer patients who fail VEGF targeted therapy. Eur Urol. 69:4–6.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Jonasch E, Agarwal N, Bhayani
S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman
M, et al: Kidney cancer, version 2.2017, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 15:804–834. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vachhani P and George S: VEGF inhibitors
in renal cell carcinoma. Clin Adv Hematol Oncol. 14:1016–1028.
2016.PubMed/NCBI
|
|
4
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tomita Y, Fukasawa S, Shinohara N,
Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, et
al: Nivolumab versus everolimus in advanced renal cell carcinoma:
Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin
Oncol. 47:639–646. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Riaz N, Havel JJ, Makarov V, Desrichard A,
Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH,
et al: Tumor and microenvironment evolution during immunotherapy
with nivolumab. Cell. 171:934–949, e916. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boutsikou E, Domvri K, Hardavella G,
Tsiouda D, Zarogoulidis K and Kontakiotis T: Tumour necrosis
factor, interferon-gamma and interleukins as predictive markers of
antiprogrammed cell-death protein-1 treatment in advanced non-small
cell lung cancer: A pragmatic approach in clinical practice. Ther
Adv Med Oncol. 10:17588359187682382018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Remon J and Besse B: Immune checkpoint
inhibitors in first-line therapy of advanced non-small cell lung
cancer. Curr Opin Oncol. 29:97–104. 2017.PubMed/NCBI
|
|
10
|
Escudier B, Motzer RJ, Sharma P, Wagstaff
J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski
PG, et al: Treatment beyond progression in patients with advanced
renal cell carcinoma treated with nivolumab in checkmate 025. Eur
Urol. 72:368–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
George S, Motzer RJ, Hammers HJ, Redman
BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM and Rini
BI: Safety and efficacy of nivolumab in patients with metastatic
renal cell carcinoma treated beyond progression: A subgroup
analysis of a randomized clinical trial. JAMA Oncol. 2:1179–1186.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Friedman CF, Proverbs-Singh TA and Postow
MA: Treatment of the immune-related adverse effects of immune
checkpoint inhibitors: A review. JAMA Oncol. 2:1346–1353. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sarocchi M, Grossi F, Arboscello E,
Bellodi A, Genova C, Dal Bello MG, Rijavec E, Barletta G, Rossi G,
Biello F, et al: Serial troponin for early detection of nivolumab
cardiotoxicity in advanced non-small cell lung cancer patients.
Oncologist. 23:936–942. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gauci ML, Laly P, Vidal-Trecan T,
Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L,
Madelaine-Chambrin I, Bagot M, Basset-Seguin N, et al: Autoimmune
diabetes induced by PD-1 inhibitor-retrospective analysis and
pathogenesis: A case report and literature review. Cancer Immunol
Immunother. 66:1399–1410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Makarious D, Horwood K and Coward JIG:
Myasthenia gravis: An emerging toxicity of immune checkpoint
inhibitors. Eur J Cancer. 82:128–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spain L, Diem S and Larkin J: Management
of toxicities of immune checkpoint inhibitors. Cancer Treat Rev.
44:51–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lipson EJ, Sharfman WH, Drake CG, Wollner
I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, et al: Durable
cancer regression off-treatment and effective reinduction therapy
with an anti-PD-1 antibody. Clin Cancer Res. 19:462–468. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martini DJ, Hamieh L, McKay RR, Harshman
LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X,
Schutz FA, et al: Durable clinical benefit in metastatic renal cell
carcinoma patients who discontinue PD-1/PD-L1 therapy for
immune-related adverse events. Cancer Immunol Res. 6:402–408. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Skoulidis F, Goldberg ME, Greenawalt DM,
Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco
SE, Gay L, et al: STK11/LKB1 mutations and PD-1 inhibitor
resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.
8:822–835. 2018. View Article : Google Scholar : PubMed/NCBI
|
